🇺🇸 FDA
Patent

US 7498353

Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses

granted A61PA61P1/16A61P31/12

Quick answer

US patent 7498353 (Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses) held by Rigel Pharmaceuticals, Inc. expires Mon Feb 26 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Mar 03 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 26 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61P, A61P1/16, A61P31/12, A61P31/14